Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence

作者：Lorenzo D’Ambrosio, Elena Fumagalli, Tommaso Martino De Pas, Margherita Nannini, Alexia Bertuzzi, Silvia Carpano, Antonella Boglione, Angela Buonadonna, Danila Comandini, Silvia Gasperoni, Bruno Vincenzi, Antonella Brunello, Giuseppe Badalamenti, Elena Maccaroni, Giacomo Giulio Baldi, Alessandra Merlini, Andrea Mogavero, Francesca Ligorio, Elisabetta Pennacchioli, Fabio Conforti, Giulia Manessi, S. Aliberti, Francesco Tolomeo, Marco Fiore, Marta Sbaraglia, Angelo Paolo Dei Tos, Silvia Stacchiotti, Maria A. Pantaleo, Alessandro Gronchi, Giovanni Grignani, Italian Sarcoma Group, Gianluca Ignazzi, Viviana Apolloni, Laura Abate Daga, Giuseppe Bianchi · 发表于：JAMA Network Open · 年份：2023 · DOI：10.1001/jamanetworkopen.2023.41522 · 被引用次数：6 · 研究领域：Gastrointestinal Tumor Research and Treatment、Gastrointestinal disorders and treatments、Gastrointestinal Bleeding Diagnosis and Treatment

Importance: Gastrointestinal stromal tumor (GIST) follow-up is recommended by international guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For these patients, the potential benefit of anticipating recurrence detection should be weighed against psychological burden and radiologic examination loads in terms of costs and radiation exposure. Objective: To evaluate the outcomes of guideline-based follow-up in low-risk GIST. Design, Setting, and Participants: This multi-institutional retrospective cohort study involving Italian Sarcoma Group reference institutions evaluated patients with GIST who underwent surgery between January 2001 and June 2019. Median follow-up time was 69.2 months. Data analysis was performed from December 15, 2022, to March 20, 2023. Patients with GIST at low risk according to Armed Forces Institute of Pathology criteria were included provided adequate clinical information was available: primary site, size, mitotic index, surgical margins, and 2 or more years of follow-up. Exposures: All patients underwent follow-up according to European Society for Medical Oncology (ESMO) guidelines. Main Outcomes and Measures: The primary outcome was the number of tests needed to identify a relapse according to ESMO guidelines follow-up plan. Secondary outcomes included relapse rate, relapse timing, disease-free survival (DFS), overall survival (OS), GIST-specific survival (GIST-SS), postrelapse OS, secondary tumor rates, and t...